Tobacco Prevention and Treatment-Related Articles
Krejci J, & Foulds J. (2003). Engaging patients in tobacco dependence treatment: Assessment and motivational techniques. Psychiatric Annuals. 33(7):436-444.
Shiffman S, & Ferguson SG. (2008). Nicotine patch therapy prior to quitting smoking: A meta-analysis.
Steinberg M, Ziedonis D, Krejci J, Brandon T. (2004). Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. Journal of Consulting and Clinical Psychology. 72(4):723-728.
Tidey J, and Williams J. (2007). Clinical indices of tobacco use in people with schizophrenia. Journal of Dual Diagnosis. 3(3/4):79-98.
Williams J. (2008). Eliminating tobacco use in mental health facilities. Journal of the American Medical Association. 299(5):571-573.
Williams J, and Gandhi K. (2008). Use of caffeine and nicotine in people with schizophrenia. Current Drug Abuse Reviews. 1:155-161.
Williams J, Steinberg M, Hanos Zimmermann M, Gandhi K, Lucas GE, Gonsalves D, Pearlstein I, McCabe P, Galazyn M, and Salsberg E. (2009). Training psychiatrists and advanced practice nurses to treat tobacco dependence. Journal of the American Psychiatric Nurses Association. 15(1):50-58.
Williams J, Ziedonis D. (2004). Addressing tobacco among individuals with mental illness or an addiction. Addictive Behaviors. 29:1067-1083.
Williams J, Ziedonis D, Abanyie F, Steinberg M, Foulds J, Benowitz N. (2005). Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia Research. 79:323-335.
Ziedonis D, Williams J, Steinberg M, & Foulds J. (2006). Addressing tobacco addiction in office-based management of psychiatric disorders: Practical considerations. Primary Psychiatry. 13(2):51-63.
Ziedonis D, Zammarelli L, Seward G, Oliver K, Guydish J,Hobart M, & Meltzer B. (2007). Addressing tobacco use through organizational change: A case study of an addiction treatment organization. Journal of Psychoactive Drugs. 39(4):451-459.